Reducing cardiovascular risk in people with diabetes and kidney disease

Brendon L Neuen and Vlado Perkovic
Med J Aust 2018; 209 (10): . || doi: 10.5694/mja18.00929
Published online: 19 November 2018

We need to move beyond managing end organ complications to reducing cardio-renal risk across the spectrum of kidney function

Type 2 diabetes mellitus is one of the greatest challenges facing the Australian health care system. The number of Australians living with diabetes has tripled over the past 25 years, and by 2025 it is expected that 3 million adults will have been diagnosed with the disease, one of the most rapid rises for any chronic condition in Australia.1

  • The George Institute for Global Health, Sydney, NSW


Brendon Neuen is funded by a John Chalmers PhD Scholarship from the George Institute for Global Health and a University Postgraduate Award from UNSW Sydney. Vlado Perkovic receives research support from the National Health and Medical Research Council (Senior Research Fellowship and Program Grant).

Competing interests:

The George Institute for Global Health provides contract research services to Janssen for trials of sodium/glucose cotransporter 2 (SGLT2) inhibitors. Brendon Neuen receives travel support from Janssen. Vlado Perkovic is the chair of a steering committee for a renal outcome study of an SGLT2 inhibitor (canagliflozin), serves on steering committees for AbbVie, Boehringer Ingelheim, GlaxoSmithKline, Janssen and Pfizer, and serves on advisory boards or speaks at scientific meetings for AbbVie, Astellas, AstraZeneca, Bayer, Baxter, Bristol-Myers Squibb, Boehringer Ingelheim, Durect, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Pfizer, Pharmalink, Relypsa, Roche, Sanofi, Servier and Vitae; all honoraria for these activities are paid to the George Institute for Global Health.

  • 1. Baker IDI Heart and Diabetes Institute, Diabetes Australia, Juvenile Diabetes Research Foundation. Diabetes: the silent pandemic and its impact on Australia. 2012. (viewed Sept 2018).
  • 2. Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol 2016; 12: 73-81.
  • 3. Kidney Health Australia. The economic impact of end-stage kidney disease in Australia: projections to 2020. 2010. (viewed Sept 2018).
  • 4. Lim WH, Johnson DW, Hawley C, et al. Type 2 diabetes in patients with end-stage kidney disease: influence on cardiovascular disease-related mortality risk. Med J Aust 2018; 209: 440-446.
  • 5. Lascar N, Brown J, Pattison H, et al. Type 2 diabetes in adolescents and young adults. Lancet Diabetes Endocrinol 2018; 6: 69-80.
  • 6. Wanner C, Tonelli M. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 2014; 85: 1303-1309.
  • 7. Heerspink HJL, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009; 373: 1009-1015.
  • 8. Palmer SC, Di Micco L, Razavian M, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 156: 445-459.
  • 9. O’Lone E, Viecelli AK, Craig JC, et al. Cardiovascular outcomes reported in hemodialysis trials. J Am Coll Cardiol 2018; 71: 2802-2810.
  • 10. Tong A, Manns B, Hemmelgarn B, et al. Establishing core outcome domains in hemodialysis: report of the Standardized Outcomes in Nephrology–Hemodialysis (SONG-HD) consensus workshop. Am J Kidney Dis 2017; 69: 97-107.
  • 11. American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes — 2018. Diabetes Care 2018; 41: S73-S85.
  • 12. Diabetes Canada Clinical Practice Guidelines Expert Committee; Lipscombe L, Booth G, Butalia S, et al. Pharmacologic glycemic management of type 2 diabetes in adults. Can J Diabetes 2018; 42: S88-S103.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.